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Background: The functional capacity of long-term survivors of submassive pulmonary embolism
(PE) is unreported. A six-minute walk distance (6MWD) <350 m and reduced heart rate recov-
ery (HRR) indicate adverse prognosis in various chronic diseases.
Methods: Long-term survivors of acute PE (January 2000eJune 2005) were invited to undergo
prospectively planned six-minute walk test (6MWT), transthoracic echocardiogram (TTE), clin-
ical and biochemical evaluation with cardiac biomarkers. HRR was calculated as the difference
between heart rate at 6-min during and at 1-min post 6MWT.
Results: 120 patients (52 males; mean age [standard deviation] e 65  14 years) were iden-
tified 7.7  1.4 years after PE. 6MWD was significantly lower than that predicted after adjust-
ment for age, sex, and height (448  114 m vs 475  89 m, p Z 0.005), and 16% (17/104) had
6MWD <350 m. Among patients with no baseline comorbidities at follow-up (Charlson comor-
bidity index Z 0), 8% (4/52) had 6MWD <350 m. Resting TTE identified 29% of patients had
raised right ventricular (RV) pulmonary pressure (pulmonary arterial systolic pressure [PASP]
>36 mmHg) and 13% had impaired RV function. Patients with 6MWD <85% predicted had signif-
icantly greater impairment of RV longitudinal function (p < 0.001), higher PASP (p < 0.001) and
pulmonary vascular resistance (p < 0.001), elevated NT-proBNP (pZ 0.03) and high-sensitivityof Cardiology, Concord Repatriation General Hospital and the University of Sydney, Hospital Road,
61 2 9767 7359; fax: þ61 2 9767 6994.
s@sydney.edu.au (L.Kritharides).
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Impaired 6MWT, HRR and cardiac function post PE 1557troponin-T (HsTropT, p Z 0.03), but similar left ventricular systolic and diastolic function, to
those with normal 6MWT.
Conclusions: Apparently well, long-term survivors of PE demonstrate impaired exercise capac-
ity, heart rate recovery, mild pulmonary hypertension, raised PVR and right ventricular
dysfunction associated with elevated NT-proBNP and HsTropT.
Crown Copyright ª 2014 Published by Elsevier Ltd. All rights reserved.Introduction
Acute pulmonary embolism (PE) is common and associated
with an early case fatality rate of 7e11%, with a reported 5-
year cumulative mortality rate of up to 32% [1]. Recent
studies identified characteristics of patients with a more
guarded long-term prognosis after PE [2]. Although
abnormal functional status has been reported in up to 41%
of patients at six months after an acute PE [3], relatively
little is known as to whether the long-term functional
impairment is present in survivors.
The six-minute walk test (6MWT) and heart rate recovery
(HRR) are practical and simple clinical tests that evaluate
the integrated exercise responses of the pulmonary and
cardiovascular systems, blood, neuromuscular units and
muscle metabolism amongst patients of different age
groups [4,5]. In a systematic review of various functional
walk tests used in cardiorespiratory assessments, the 6MWT
was shown to be easier to administer, better tolerated and
more reflective of activities of daily living than other walk
tests [6], and was easily incorporated into clinical practice.
HRR after exercise assesses the changes in autonomic tone
that occur immediately after cessation of exercise and
reduced HRR has been shown to be a strong predictor of
long-term adverse cardiac outcomes in healthy people [7]
and in patients with pulmonary hypertension [8].
The present study examined the functional status of
long-term survivors of acute PE using the 6MWT, HRR and
echocardiography. Our primary hypothesis was that appar-
ently well, long-term survivors of PE might demonstrate
impaired functional capacity. If observed, a secondary aim
of the study was to determine if the functional impairment
was independent of patients’ comorbidities, and/or related
to subclinical right ventricular (RV) dysfunction or pulmo-
nary hypertension.Methods
Study population
Consecutive patients (n Z 1023) admitted with a principal
diagnosis of acute PE between January 2000 and June 2005
were identified retrospectively from a tertiary institution
(Concord Hospital, Sydney, Australia) as previously re-
ported [1,9]. Confirmed PE was defined according to pub-
lished guidelines and required both documented clinical
diagnosis and/or treatment of acute PE with therapeutic
anticoagulation by the attending physician and an imaging
study confirming the diagnosis of acute PE [10].Important comorbidities during index PE admission,
based on the International Classification of Disease, Tenth
Revision, were recorded for each patient. The overall co-
morbid status and short-term mortality risk of each patient
were assessed and given a Charlson Comorbidity Index (CCI)
score [11] and a simplified Pulmonary Embolus Severity
Index (PESI) score respectively [12]. A CCI score 3 is
associated with high mortality risk and independently pre-
dicts long-term outcome following acute PE [13]. Patients
with a simplified PESI score 1 are classified as high risk and
have a 30-day mortality of 10.9% [12].
Study protocol
The outcome status of all patients was first ascertained
from the state death registry (New South Wales, Australia)
with 100% complete follow-up. All patients who survived
until 1st January 2010 (nZ 466 patients, at least four years
after the index PE) were invited by letter to prospectively
participate in the study. Patients were subsequently con-
tacted by telephone to arrange follow-up appointments.
The exclusion criteria were: 1) patients declined to
participate; 2) patients had dementia; 3) patients had
relocated interstate or overseas; 4) did not consent to
blood collection to be taken at time of review; or 5) were
physically too infirm or otherwise incapable of attending for
follow up review.
Patients who agreed to participate underwent the
following assessments: 1) clinical review and examination;
2) electrocardiography to assess baseline heart rate and
underlying cardiac rhythm; 3) spirometry to assess venti-
latory function and exclude obstructive or restrictive lung
disease; 4) echocardiography; 5) 6MWT to assess functional
capacity; 6) blood tests including fasting lipid and glucose,
and cardiac biomarkers [high-sensitivity troponin-T
(HsTropT), high-sensitivity C-reactive protein (HsCRP) and
N-terminal prohormone of brain natriuretic peptide (NT-
proBNP)].
The study was conducted in accordance with Good
Clinical Practice and the Declaration of Helsinki and was
approved by the institutional Human Research Ethics
Committee, with written informed consent obtained from
each patient.
Ventilatory function, six minute walk test and heart
rate recovery
Spirometry was measured according to published criteria
[14]. The presence of any underlying obstructive lung dis-
ease was classified according to the GOLD criteria [15]. The
1558 V. Chow et al.6MWT was administered by a single researcher (V.C.) ac-
cording to published guidelines [4]. The six-minute walk
distance (6MWD) was defined as the total distance walked
during the 6MWT. For each patient, predicted values were
derived from the recommendations of Enright and Sherill.
For males, predicted 6MWD in meters (m)Z [(7.57  height
cm)  (5.02  age)  (1.76  weight kg)  309]. For fe-
males, predicted 6MWD Z [(2.11  height cm)  (5.78 
age)  (2.29  weight kg) þ 667] [16].
Heart rate and oxygen saturation were obtained via a
pulse oximeter and recorded at baseline and continuously
during the test and into the first minute of the recovery
period. HRR has been increasingly utilized to help assess
risk and functional autonomic status in both healthy in-
dividuals and in patients with various diseases. At present,
there are no national or international standards for
obtaining and reporting HRR [17]. For our study, we defined
HRR as the difference between the heart rate recorded at
6 min during the 6MWT and at 1 min of the recovery period
immediately after the 6MWT [17]. The degree of dyspnea
was assessed by the modified Borg dyspnea scale prior to
and immediately upon the completion of the walk test [4].
Definition of abnormal six minute walk test
To the best of our knowledge, there are currently no
standardized definitions of abnormal 6MWD in patients
following acute PE. However, previous studies have re-
ported on the 6MWD in various disease states. In chronic
obstructive pulmonary disease (COPD), a 6MWD <350 m is
considered abnormal [18] whilst a distance of 54 m or 15%
below the mean 6MWD constituted the minimum difference
that was associated with patients’ subjective symptoms in
COPD [19]. Furthermore, in a more recent study, Puhan
et al. reported that a minimal difference of 26  2 m on
6MWT constituted an objective change in functional status
in patients with severe COPD [20]. In community-dwelling
older patients and survivors of subacute stroke, a dis-
tance of 20 m or 9% below the mean 6MWD was considered
to represent a meaningful change in functional status [21].
According to Enright’s 6MWD prediction formulae, the
lower limit of normal 6MWD for healthy adults was defined
as 153 m (men) and 139 m (women) below their respective
predicted distances [16]. Based on the above, a 6MWD that
was either 15% less than the predicted 6MWD, or was at
least 153 m (men) or 139 m (women) below predicted based
on Enright’s formulae, were considered abnormal for the
present study.
Echocardiography and ventricular function
Resting echocardiography was performed to assess RV
function and estimate the pulmonary artery systolic pres-
sure (PASP). The PASP was derived as the sum of the
tricuspid regurgitant pressure gradient obtained from
continuous-wave Doppler and the right atrial pressure as
estimated from the inferior vena cava. A PASP >36 mmHg
was considered abnormal and indicative of mild pulmonary
hypertension whilst PASP >50 mmHg was indicative of
moderately severe pulmonary hypertension according to
guidelines [22]. RV longitudinal function was measured bydetermining the tricuspid annular plane systolic excursion
(TAPSE) [22]. A TAPSE cutoff of <1.8 cm is prognostically
important in patients with pulmonary hypertension and was
considered indicative of abnormal RV function in the pre-
sent study [23]. Non-invasive estimation of the pulmonary
vascular resistance (PVR) by Doppler analysis is a reliable
and well-validated method compared with invasive PVR
measurements [24,25]. In this study, the PVR was obtained
non-invasively by Doppler analysis on echocardiography,
and PVR >2 Wood units is considered abnormal [26].
The right and left sided cardiac chambers were analyzed
by conventional 2D parameters that included: the ratio of
RV and left ventricular (LV) end-diastolic diameters; the
ratio of RV:LV end-diastolic areas; the RV fractional area
change (RVFAC); the ratio of right atrial (RA) and left atrial
(LA) end-systolic areas [27]. The LV ejection fraction (EF)
was measured by volumetric (Simpson’s biplane) method,
consistent with published guidelines [27]. Impaired LV sys-
tolic function was defined as Simpson’s LVEF <50% and
RVFAC <35%, TAPSE <1.8 cm for RV dysfunction. RV and RA
dilation were defined as RV:LV end-diastolic area ratio >0.6
and RA:LA end-systolic area ratio >1.0 respectively [27]. LV
diastolic function was assessed as per published guidelines
[28], and all measurements were averaged over 3 consec-
utive cardiac cycles with intra-observer variation for these
parameters consistent with reported literature.
Statistical analysis
Data were summarized as frequencies and percentages for
categorical variables. Continuous variables were presented
as mean  standard deviation. Comparison of two groups
used the unpaired t test for continuous variables and c2
tests or the Fisher exact test for dichotomous variables.
The paired t test was used to compare the difference in
predicted and actual 6MWD for each patient in the cohort.
A two-tailed p value of <0.05 was used as a cut-off for
statistical significance. Statistical analysis was performed
using GraphPad Prism 5.01 (GraphPad Software, San Diego,
Calif), and SPSS (Version 16.0, SPSS Inc., Chicago, Ill).Results
In total, there were 466 survivors of PE identified, of whom
266 met the inclusion criteria. Of those who were excluded,
43% were physically too infirm or otherwise incapable of
attending the follow up review, 28% had dementia or were
in residential care, 24% had moved out of metropolitan
Sydney and 5% spoke limited English. Of the remaining
eligible survivors, 120 patients (45% of those eligible) con-
sented to participate in the study (Fig. 1).
Clinical evaluation
Table 1 summarizes the characteristics of the 120 patients.
There were 52 males (43%). Mean age for the cohort was
65  14 years with follow-up of 7.7  1.4 years since their
index PE event. The majority of follow-up patients had a
simplified PESI score <1 implying low risk, hemodynami-
cally stable index PE.
Figure 1 Flow chart of enrollment of patients for the study.
COPD Z chronic obstructive pulmonary disease; NESB Z non-
english speaking background, PE Z pulmonary embolism.
Table 1 Summary of patient baseline characteristics.
Patients
(n Z 120)
Demographics at follow-up
Age, yr 65  14
Male sex 52 (43)
Current smoker 8 (7)
Medical history at follow-up
Hyperlipidemia 45 (38)
Hypertension 44 (37)
IHD 14 (12)
Diabetes 13 (11)
Atrial fibrillation 13 (11)
Chronic lung disease 11 (9)
Heart failure 9 (8)
Stroke 5 (4)
Sleep apnoea 4 (3)
Valve repair/replacement 2 (2)
Pulmonary arterial hypertension on
treatment
1 (1)
Charlson comorbidity index (CCI)
At time of index PE 0.7  1.2
CCI > 3 (Age-unadjusted) 12 (10)
At time of follow-up- 0.9  1.3
CCI > 3 (Age-unadjusted) 14 (12)
Risk factor for PE at time of diagnosis
Immobilization 29 (24)
Malignancy 19 (16)
Previous PE/DVT 17 (14)
Hypercoagulability (prothrombotic
screen þve)
17 (14)
Recent surgery within 6 weeks 16 (13)
Family history of PE 9 (8)
Clinical measurement at time of
follow-up
BMI 30  6
SBP, mmHg 130  14
DBP, mmHg 79  8
Oxygen saturation, % 96  2
Pulse, bpm 74  12
NYHA class > 1 18 (15)
Medication at time of follow-up
Statin 43 (36)
ACE inhibitor or angiotensin receptor
inhibitor
42 (35)
Warfarin 42 (35)
Aspirin 20 (17)
Beta-blocker 19 (16)
Clopidogrel 5 (4)
Cardiac biomarkers at time of Follow-up
NT-proBNP (pmol/L) 42  100
NT-proBNP > 13 pmol/L 51 (43)
HsTropT (ng/L) 7.9  9.1
HsTropT > 14 19 (16)
HsCRP (mg/L) 5.0  7.9
Outcomes
Simplified PESI score on admission 0.6  0.8
Simplified PESI score >1 50 (42)
Concurrent DVT 26 (22)
Recurrent PEa 29 (24)
(continued on next page)
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The mean age-unadjusted CCI score for the study cohort at
the time of their index PE was 0.7  1.2, and this only
increased to 0.9  1.3 at follow-up, thus suggesting a
relatively low burden of comorbid diseases in the majority
of patients. Age-unadjusted CCI >3 was observed in 10% of
patients at the time of index PE and 12% of patients at
follow-up. Sixteen percent of patients were found to have
HsTropT >14 ng/L and 43% had NT-proBNP >13 pmol/L at
their follow-up assessment.
One patient was diagnosed with chronic thromboembolic
pulmonary hypertension (CTEPH) four years following his
initial PE and had received phosphodiesterase inhibitor
therapy for eighteen months prior to follow-up. Another
patient had likely CTEPH with raised pulmonary pressure on
echocardiography and a single persistent segmental perfu-
sion defect on ventilation perfusion scan. However, due to
significant comorbidities, the patient did not consent for
right heart catheterization and pulmonary angiography for
definitive diagnosis. Eleven patients had documented
chronic obstructive pulmonary disease or restrictive lung
disease on spirometry, based on published criteria [15].
Functional capacity
Of the 120 patients studied, 11 were excluded because of
chronic obstructive pulmonary disease or restrictive lung
disease confirmed on spirometry, and another five were
excluded because of orthopedic/neuromuscular impair-
ment, precluding meaningful functional assessment. Of the
Table 1 (continued )
Patients
(n Z 120)
Despite anticoagulation 16 (55)
Bleeding complications 13 (11)
Duration of anticoagulation
Lifelong anticoagulation 45 (38)
Duration of temporary
anticoagulation (days)
223  151
Values are presented as mean  SD or absolute number (%).
ACEZ angiotensin converting enzyme, BMIZ body mass index,
CCI Z Charlson comorbidity index, chronic lung
disease Z chronic obstructive or restrictive lung disease,
DBP Z diastolic blood pressure, DVT Z deep vein thrombosis,
HsCRP Z high-sensitivity C-reactive protein, HsTropT Z high-
sensitivity troponin-T, IHD Z ischaemic heart disease, NT-
proBNP Z N-terminal prohormone of brain natriuretic peptide
(To convert pmol/L to pg/ml, multiply pmol/L by 8.457),
NYHAZ New York Heart Association, PEZ pulmonary embolus,
PESI scoreZ pulmonary embolus severity index, SBPZ systolic
blood pressure.
a Recurrent PE was defined as recurrence of symptoms
consistent with PE and repeat imaging (VQ or CTPA) confirming
new regions of PE.
Table 2 Six minute walk test and ventilatory function
assessment.
Overall patients
(n Z 104)
Six minute walk test
6MWT distance, mean  SD (meters) 453  109
6MWT distance <350 m 17 (16)
Abnormal 6MWTa 26 (25)
Abnormal 6MWT based on
Enright’s LLNb
11 (11)
Heart rate recovery,
mean  SD (bpm)
25  13
Males
(n Z 43)
Females
(n Z 61)
Six minute walk test
Predicted 6MWD (meters) 490  86 473  90
Actual 6MWD (meters) 461  113 447  108
Abnormal 6MWTa 14 (33) 12 (20)
6MWT distance <350 m 6 (14) 11 (18)
Borg scale 2.8  2.4 2.7  2.3
Heart rate recovery (bpm) 22  11 27  15
Beta blockers/calcium
channel blockers
14 (33) 8 (13)
Spirometry
FEV1 (liters) 2.5  0.6 2.1  0.6
FVC (liters) 3.2  0.7 2.6  0.7
FEV1/FVC 0.8  0.1 0.8  0.1
Values are presented as mean  SD or absolute number (%).
6MWT Z six minute walk test; 6MWD Z six minute walk dis-
tance; FEV1 Z forced expiratory volume in 1 s; FVCZ forced
vital capacity; LLN Z lower limit of normal.
a 6MWT distance <85% predicted in accordance with predic-
tion formulae by Enright and Sherill [16].
b For the lower limit of normal 6MWD based prediction
formulae by Enright and Sherill, subtract 153 m and 139 m for
males and females respectively [16].
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6MWD <350 m, 26 (25%) had abnormal 6MWT defined as a
6MWD that was 15% less than predicted for age, sex and
height and 11 (11%) had abnormal 6MWT defined as an ab-
solute 6MWD below the lower limit of normal (Table 2). The
mean oxygen saturation at rest was 96  2%. Thirteen pa-
tients out of 104 (12.5%) reported an increase in the
modified Borg Scale during 6MWT. Of these, 10/104 (9.6%)
reported modified Borg Scale score of >5 and 6/104 (6%)
recorded oxygen desaturation to <90% during 6MWT which
returned to baseline oxygen saturation during the recovery
period.
Of the studied population, the 6MWD was significantly
lower than that predicted for age, sex and height
(448  114 vs 475  89 m, p Z 0.001, Fig. 2). The mean
6MWD for male patients was 461  113 m compared to the
predicted 6MWD of 490  86 m (p Z 0.02, Table 2). The
mean HRR for males was 22  11 bpm. For female patients,
the mean 6MWD was 447  108 m compared to the pre-
dicted 6MWD of 473  90 m (pZ 0.03), and their mean HRR
was 27  15 bpm.
To ensure our results were not confounded by those
patients in atrial fibrillation, we separately analyzed the 94
patients in sinus rhythm. This showed similar results with a
significant reduction in 6MWD relative to that predicted for
age, sex and height (456  110 vs 477  90 m, p Z 0.007)
with 15 (16%) of these patients having a 6MWD <350 m.
Transthoracic echocardiography (TTE) and
biochemical and cardiac biomarkers
Resting TTE assessment showed RV dilation, reduced lon-
gitudinal function (TAPSE), raised PASP and PVR in 7%, 13%,
29% and 21% of patients respectively. There were 12 (12%)
patients with impaired LV contractility (Simpson’s biplaneEF <50%). Reduced E’ velocity and E/E’>8 were noted in
19% and 33% of patients respectively (Table 3). Patients
with 6MWD <85% predicted had significantly greater
impairment of RV longitudinal function assessed by TAPSE
(p < 0.001), higher PASP (p < 0.001) and PVR (p < 0.001),
but similar LV systolic and diastolic function to those pa-
tients with normal 6MWT (Table 4). Similar trends were also
observed in patients with abnormal 6MWT based on
Enright’s definition of lower limit of normal (Supplementary
Table 1). There were significantly higher levels of cardiac
biomarkers NT-proBNP (p Z 0.03) and HsTropT (p Z 0.03)
in patients with abnormal 6MWT (Table 4).
Impact of comorbidities on functional capacity
To assess the impact of underlying comorbidities on the
observed functional impairment on 6MWT, we compared
the characteristics of patients with no comorbidities at
follow-up (age-unadjusted CCI Z 0) to those with any un-
derlying comorbidities (age-unadjusted CCI 1) (Table 5).
The 52 patients that were without underlying comorbidities
at the time of follow-up were significantly younger
Figure 2 Predicted (mean  SD, 475  89 m) and actual
(mean  SD, 448  114 m) 6MWD amongst the entire cohort of
104 patients who underwent 6MWT. pZ 0.001 for predicted vs
actual 6MWD (paired t test).
Table 3 Echocardiographic assessment.
All patients
(n Z 104)
RV and LV chamber size
RVEDD > 42 mm (Basal) 2 (2)
RVEDD > 36 mm (Mid) 6 (6)
RVEDA:LVEDA ratio > 0.6 7 (7)
RA:LA area ratio > 1.0 11 (11)
RV function & hemodynamics
RV FAC < 35% 11 (11)
TAPSE < 1.8 cm 14 (13)
PASP > 36 mmHg 30 (29)
PASP > 50 mmHg 5 (5)
PVR > 2 Wood unit 22 (21)
LV function
Simpson’s biplane EF (%) 59.8  8.3
Diastolic function
LV E’ (average) (cm/sec) 9.6  2.9
LV E/E’ 8.1  2.9
Abnormal E’ < 8 (septal) or
E’ < 10 cm/s (lateral)
19 (19)
Values are presented as mean  SD or absolute number (%).
E’ Z early diastolic myocardial tissue Doppler velocity
measured at septum or lateral mitral annulus; E/E’ Z ratio of
mitral peak velocity of early filling (E) to early diastolic mitral
annual velocity (E’); EF Z ejection fraction; LA Z left atrium;
LVZ left ventricle; LVEDAZ left ventricular end diastolic area;
PASP Z pulmonary artery systolic pressure; PVR Z pulmonary
vascular resistance; RA Z right atrium, RV Z right ventricle;
RVEDA Z right ventricular end diastolic area; RVEDD Z right
ventricular end diastolic diameter; RV FAC Z Right ventricular
fractional area change; TAPSE Z tricuspid annular plane sys-
tolic excursion.
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(pZ 0.01), lower Borg Scale (pZ 0.009) and lower HsTropT
(p Z 0.004) and serum creatinine levels (p Z 0.001) than
patients with CCI 1. In addition, there were fewer pa-
tients with abnormal NT-proBNP and HsTropT in the CCIZ 0
group, and no patient with CCI Z 0 was in New York Heart
Association functional class II or greater during the 6MWT
compared to the CCI 1 cohort. Among patients with CCI
1, 31% (16/51) had a 6MWD that was significantly less than
predicted.
Despite the more favorable characteristics of patients
without comorbidity, 10 patients (19%) with CCI Z 0
demonstrated 6MWD <85% of that predicted. In these 10
patients, the 6MWD was significantly lower (366  136 vs
510  78 m, p < 0.001) and RV function defined by TAPSE
was significantly more impaired (p Z 0.03) than in those
patients with CCI Z 0 and normal 6MWT. Furthermore, the
PASP (p Z 0.008) and PVR (p Z 0.003) were significantly
higher whilst LV systolic and diastolic function was similar
to those patients with CCI Z 0 and normal 6MWT. On
multivariable analysis, raised PVR was the only indepen-
dent predictor of abnormal 6MWT [OR 1.7 (1.2e2.3),
p Z 0.001] (Supplementary Table 2).
Discussion
In this study, we report for the first time significant func-
tional impairment in up to 25% of apparently well PE sur-
vivors after a mean follow-up of 7.7  1.4years.
Furthermore, among PE survivors without comorbidity, 19%
had below normal 6MWD and had significantly lower HRR
compared to their predicted estimates. The functional
impairment was associated with echocardiographic evi-
dence of RV dysfunction and raised PVR but not LV systolicor diastolic dysfunction. The increased levels of biochem-
ical markers of myocardial strain and injury are consistent
with significant right heart pathology in these patients.
Klok et al. observed that at a mean of 40 months
following acute PE, 56% of patients reported exertional
dyspnea and 70% experienced new or worsened dyspnea
[29]. In a subsequent study, this high level of exertional
dyspnea was thought mainly attributable to pre-existing
comorbidities [30]. The CCI, when incorporated into a risk
model, has good discriminatory power for predicting long-
term mortality following acute PE [13]. Contrary to the
study by Klok et al., by examining the functional status of
patients without comorbidities as defined by a CCI score of
0, our study indicates that there is significant long-term
functional impairment in many patients after PE that
cannot be simply explained by comorbidities.
HRR after exercise reflects changes in autonomic tone
due to sympathetic withdrawal and parasympathetic reac-
tivation and has prognostic implications. A delayed or
reduced HRR was shown to be a strong predictor of subse-
quent long-term mortality in apparent healthy people, with
a HRR <25 bpm at one minute post exercise conferring a
2.2-fold increased risk of sudden cardiac death from
myocardial infarction [31]. Cole et al. reported an HRR
<12 bpm independently predicted a 2-fold increased risk in
all-cause mortality amongst a large group of patients who
Table 4 Right and left ventricular function, cardiac biomarkers and heart rate recovery stratified by 6MWT.
Normal 6MWT (n Z 78) Abnormal 6MWTa (n Z 26) p Value
RV and LV chamber size
RVEDD > 42 mm (basal) 1 (1) 1 (4) 0.45
RVEDD > 36 mm (mid) 2 (3) 4 (15) 0.04*
RVEDA:LVEDA ratio 0.42  0.1 0.45  0.09 0.25
RA:LA area ratio 0.78  0.2 0.77  0.2 0.91
RV function & hemodynamics
RV FAC (%) 50.4  9.3 44.9  11.6 0.02*
TAPSE < 1.8 cm 3 (4) 11 (42) <0.001*
PASP > 36 mmHg 14 (18) 16 (62) <0.001*
PVR > 2 Wood unit 6 (8) 16 (62) <0.001*
LV function
Simpson’s EF (%) 60.4  8.2 58.1  8.6 0.26
LV E’ (average) (cm/sec) 9.5  3.1 9.7  2.2 0.75
LV E/E’ 7.9  3.1 8.2  2.5 0.67
Abnormal E’ 17 (22) 2 (8) 0.14
Biomarkers
NT-proBNP (pmol/L) 34.2  8.7 84.2  30.5 0.03*
HsTropT (ng/L) 6.9  8.2 11.2  10.3 0.03*
Heart rate recovery (bpm) 28  13 18  13 0.002*
Values are presented as mean  SD or absolute number (%).
6MWTZ six minute walk test; Abnormal E’Z <8 (septal) or E’<10 cm/s (lateral); E’Z early diastolic myocardial tissue Doppler velocity
measured at septum or lateral mitral annulus; E/E’ Z ratio of mitral peak velocity of early filling (E) to early diastolic mitral annual
velocity (E’); EF Z ejection fraction; HsTropT Z high-sensitivity troponin-T; LA Z left atrium; LV Z left ventricle; LVEDA Z left
ventricular end diastolic area; NT-proBNP Z N-terminal prohormone of brain natriuretic peptide; PASP Z Pulmonary artery systolic
pressure; PVRZ pulmonary vascular resistance; RAZ right atrium, RVZ right ventricle; RVEDAZ right ventricular end diastolic area;
RVEDDZ right ventricular end diastolic diameter; RV FACZ right ventricular fractional area change; TAPSE Z tricuspid annular plane
systolic excursion.
*Denotes p < 0.05.
a 6MWT distance <85% predicted in accordance with prediction formulae by Enright and Sherill [16].
1562 V. Chow et al.underwent stress testing [7]. Furthermore, in patients with
idiopathic pulmonary arterial hypertension, abnormal HRR,
defined as HRR <16 bpm, was an independent predictor of
adverse outcome associated with at least a 5-fold increased
risk of clinical worsening and progression of the disease
state based on the 6MWT [8]. At present, there is a lack of
standardization of HRR analyses and reporting in the liter-
ature. Adabag et al. reviewed 74 studies that incorporated
HRR analyses and found the HRR results were frequently
reported either as a continuous and/or a categorical vari-
able [17]. From their analyses, an abnormal HRR when
defined as the difference between the maximum heart rate
and heart rate 1 min after exercise appears to be in the
range from 8 to 17 bpm.
In the present study, reduced HRR appears to be a
marker of functional impairment as reflected by a signifi-
cantly reduced 6MWD amongst those patients with reduced
HRR irrespective of whether the latter was expressed as a
continuous or categorical variable. There were 32 patients
out of the 104 studied who had an abnormal HRR defined as
<16 bpm and this correlated with a reduced 6MWD. In
addition, the mean HRR was significantly lower amongst
patients with abnormal 6MWT (18  13 bpm vs 28  13 bpm,
pZ 0.002). It is possible that the abnormal HRR observed in
our long-term survivors of PE reflected potentially
continued sympathetic activation and a lack of normal
parasympathetic reactivation after exercise. Such behavior
would not be dissimilar to heart failure patients with poorfunctional capacity and blunted parasympathetic reac-
tivation [32]. Additional factors influencing the recovery in
heart rate of these patients may include the cardiorespi-
ratory effects of impaired RV function and increased PVR
observed in the present study.
Our findings are supported by previous studies with
shorter follow-up. Stevinson et al. observed either an
abnormal RV function on echocardiography or a reduced
6MWD in 41% of previously healthy patients at six months
after acute PE [3]. Golpe et al. reported that despite total
resolution of intraluminal filling defects on computed to-
mography pulmonary angiography in 79% of patients at six
months, residual RV dysfunction or pulmonary hypertension
on echocardiography was present in 23% of patients [33].
Furthermore, persistent RV, pulmonary artery trunk dila-
tion and reduced acceleration time of the pulmonary
ejection were observed in 36 patients after a mean of 3.1
years following acute PE [34]. In our study, impaired RV
longitudinal shortening and raised PASP were evident
despite many years after the index PE, affecting 13% and
29% of these long-term survivors respectively. In addition,
higher levels of HsTropT and NT-proBNP were observed
amongst patients with abnormal 6MWT despite absence of
LV dysfunction, suggesting that the echocardiographic
finding of RV dysfunction is functionally significant.
There are a number of postulated explanations for the
persistent RV dysfunction that had been derived from ani-
mal models of PE. Subendocardial RV hypoperfusion in dogs
Table 5 Charlson comorbidity index analysis.
Charlson comorbidity
index Z 0 N Z 52
Charlson comorbidity
index  1 N Z 52
p Value
Age, year 61  14 72  12 <0.001*
Male sex 14 (27) 29 (56) 0.005*
BMI 30  6 29  6 0.45
Oxygen saturation (%) 97  2 97  2 0.53
Heart rate (bpm) 74  11 73  13 0.47
6MWT and HRR
6MWT distance (meters) 482  107 423  105 0.007*
6MWT distance <350 m 4 (8) 13 (27) 0.02*
Abnormal 6MWTa 10 (19) 16 (31) 0.26
Abnormal 6MWT Enright’s LLNb 5 (10) 6 (12) 0.76
Borg scale 2.5  2.0 3.4  2.8 0.009*
Heart rate recovery (bpm) 29  14 22  12 0.014*
Beta blockers/CCB 5 (10) 17 (33) 0.007*
Echocardiography
TAPSE (cm) 2.2  0.3 2.0  0.3 0.004*
TAPSE < 1.8 cm 3 (6) 11 (21) 0.04*
PASP (mmHg) 30.5  6.4 34.9  7.7 0.003*
PASP > 35 mmHg 11 (21) 19 (37) 0.08
Biomarkers
NT-proBNP (pmol/L) 27  66 66  127 0.06
Abnormal NT-proBNP 17 (33) 36 (69) 0.001*
Creatinine (mmol/L) 74  15 94  33 0.001*
HsTropT (ng/L) 4.4  3.8 11.3  11.0 <0.001*
Abnormal HsTropT 4 (8) 16 (31) 0.005*
Hemoglobin (g/L) 140  13 135  17 0.14
D-Dimer (mg/L) 0.3  0.2 0.7  1.6 0.08
HsCRP (mg/L) 4.2  4.6 5.9  10.5 0.31
Outcomes
Simplified PESI Score 0.5  0.8 0.7  0.8 0.30
CCI (Age unadjusted) 0 1.8  1.1 <0.001*
Recurrent PE 15 (29) 16 (31) 1.00
Lifelong anticoagulation 19 (37) 29 (56) 0.08
NYHA > 1 0 15 (29) <0.001*
Values are presented as mean  SD or absolute number (%).
6MWT Z six minute walk test; BMIZ body mass index; CCB Z calcium channel blockers; CCI Z Charlson comorbidity index;
HsCRP Z high-sensitivity C-reactive protein; HsTropT Z high-sensitivity troponin-T; HRR Z heart rate recovery; LLN Z lower limit of
normal; NT-proBNP Z N-terminal prohormone of brain natriuretic peptide; NYHA Z New York Heart Association; PASP Z Pulmonary
artery systolic pressure; PE Z pulmonary embolism; PESI scoreZ pulmonary embolus severity index, TAPSE Z tricuspid annular plane
systolic excursion.
*Denotes p < 0.05.
a 6MWT distance <85% predicted in accordance with prediction formulae by Enright and Sherill [16].
b For the lower limit of normal 6MWD based prediction formulae by Enright and Sherill, subtract 153 m and 139 m for males and females
respectively [16].
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light and electron microscopy in rats [36] have been re-
ported. Acute inflammation following RV damage ensues,
with increased chemokine synthesis (monocyte chemo-
attractant protein [MCP-1]) [37], chemotaxis, infiltration of
granulocytes [38] and CD68 positive scavenger macrophages
[39] into the RV myocardial tissue leading to intrinsic RV
dysfunction at a cellular level. These acute effects may
evolve into long-term irreversible RV or pulmonary circu-
lation dysfunction leading to eventually reduced exercise
capacity as observed in the current study.
Our results are derived from a single-center and will
require further validation in larger cohorts. Nonetheless, tothe best of our knowledge, the present study represents the
largest cohort of long-term survivors of PE to undergo a detail
prospective physiological evaluation many years after their
index PE event. Our data are consistent and extend the re-
sults of prior studies that were of shorter follow-up duration
[3,30]. While the 6MWT and HRR provide indirect assess-
ments of cardiopulmonary functional capacity as compared
to the gold standard of cardiopulmonary exercise stress
testing and direct evaluation of gas exchange, the 6MWT has
been shown to have prognostic value in patients with stable
coronary heart disease. In addition, it has similar discrimi-
native ability to that of exercise treadmill capacity [40] and
cardiopulmonary exercise testing [41] in predicting adverse
1564 V. Chow et al.cardiac outcomes. Finally, the true incidence of long-term
functional impairment is likely underestimated in the pre-
sent study as only eligible long-term survivors of PE well
enough to attend our clinic (120/266, 45%) were recruited.
Conclusions
The present study reports, for the first time, that amongst
long-term survivors of submassive PE reduced 6MWD and
HRR appear to persist despite years after the index PE
event. This is associated with mild pulmonary hypertension,
right ventricular dysfunction, raised PVR, elevated NT-
proBNP and HsTropT. Thus, patients who survived an acute
PE may demonstrate functional impairment years later, a
previously unrecognized long-term consequence of PE.
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